IACS-9571 is a selective inhibitor of EZH2, a key epigenetic regulator, primarily investigated for its potential in cancer therapy. It targets specific pathways involved in tumor growth and survival by degrading EZH2 protein, thereby inhibiting cancer cell proliferation. Researchers are exploring its use in preclinical models to assess efficacy against various cancers, including those resistant to conventional therapies such as diffuse large B-cell lymphoma. It is also evaluated for enhancing existing treatments in combination therapies, advancing precision medicine by exploiting molecular vulnerabilities in cancer cells.